| 抗生素对免疫检查点抑制剂治疗非小细胞肺癌疗效影响的Meta分析 |
| |
| 引用本文： | 霍庚崴,宋莹,陈卫东,种道群,贾沙沙,陈鹏. 抗生素对免疫检查点抑制剂治疗非小细胞肺癌疗效影响的Meta分析[J]. 中国肿瘤生物治疗杂志, 2021, 28(2): 165-170 |
| |
| 作者姓名： | 霍庚崴 宋莹 陈卫东 种道群 贾沙沙 陈鹏 |
| |
| 作者单位： | 1. 天津医科大学 肿瘤医院 肺部肿瘤内科 国家肿瘤临床医学研究中心 天津市肿瘤防治重点实验室 天津市恶性肿瘤临床医学研究中心 天津市肺癌诊治中心 天津市肿瘤免疫与生物治疗重点实验室，天津 300060;a. 济宁市第一人民医院 肿瘤科;b. 药学部，山东 济宁 272000 |
| |
| 基金项目： | 天津市科学技术委员会重大项目（No. 18ZXDBSY00050） |
| |
| 摘 要： | 目的:通过Meta分析的方法评价抗生素对免疫检查点抑制剂治疗非小细胞肺癌(non-small lung cancer,NSCLC)疗效的影响.方法:检索Pubmed、Cochrane Library、EMbase、EBSCO循证医学数据库、中国生物医学文献数据库(CBM)、中国知网(CNKI)中收录的关于抗生素对免疫检...
|
| 关 键 词： | 非小细胞肺癌 免疫检查点抑制剂 抗生素 程序性死亡受体1 程序性死亡配体1 |
| 收稿时间： | 2020-08-15 |
| 修稿时间： | 2021-01-10 |
Effect of antibiotics on treatment efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A Meta-analysis |
| |
| HUO Gengwei,SONG Ying,CHEN Weidong,CHONG Daoqun,JIA Shash,CHEN Peng. Effect of antibiotics on treatment efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A Meta-analysis[J]. Chinses Journal of Cancer Biotherapy, 2021, 28(2): 165-170 |
| |
| Authors: | HUO Gengwei SONG Ying CHEN Weidong CHONG Daoqun JIA Shash CHEN Peng |
| |
| Abstract: | Objective: To investigate the effects of antibiotics on the treatment efficacy of immune checkpoint inhibitors in NSCLC (non-small cell lung cancer) with Meta-analysis.Methods: Literatures regarding the effects of antibiotics on the treatment efficacy of immune checkpoint inhibitors in NSCLC were searched in Pubmed, Cochrane Library, Embase, EBSCO, Chinese Biomedical Literature Database(CBM) and Chinese Journal Full-text Database(CNKI). RevMan 5.3 software was used in this Meta-analysis.Results: Fourteen articles involving 2 505 NSCLC patients were included in this study. Meta-analysis showed that the application of antibiotics could significantly shorten the PFS (HR=1.14, 95%CI =1.04-1.26, P=0.005) and OS (HR=1.30, 95%CI =1.14-1.47, P<0.0001) of NSCLC patients treated with immune checkpoint inhibitors.Conclusion: Application of antibiotics before, concurrently or after immune checkpoint inhibitors in the treatment of NSCLC may significantly shorten PFS and OS, resulting in adverse effect on treatment efficacy. |
| |
| Keywords: | non-small lung cancer(NSCLC)|immune checkpoint inhibitor|antibiotics|programmed death 1(PD-1)|programmed death ligand 1(PDL-1) |
|
| 点击此处可从《中国肿瘤生物治疗杂志》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤生物治疗杂志》下载全文 |
